Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With Metastatic RET Fusion–Positive Sarcoma: A Case Report
Anna-Sophia Mast, Ursula Leuschner, Stefanie Schulte, Markus Mezger, Martin Ebinger · 2026
Read Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With Metastatic RET Fusion–Positive Sarcoma: A Case Report by Anna-Sophia Mast, Ursula Leuschner, Stefanie Schulte, Markus Mezger, Martin Ebinger (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13252966.txt.
Description
Anna-Sophia Mast and co-authors describe first-line selpercatinib treatment for a nine-month-old infant with metastatic sarcoma in a 2026 case report. Infantile fibrosarcoma is the commonest soft tissue sarcoma of infancy and usually responds well to surgery or standard chemotherapy. This baby's tumor was a look-alike variant lacking the usual gene fusion, carrying instead a fusion involving the RET gene.
Selpercatinib blocks the RET protein precisely, and it had shown strong results in older children and adults with RET-driven tumors. Given as the first treatment here, it produced rapid shrinkage of the widespread disease. The response held, and after a year of therapy the main tumor had regressed substantially. The authors note the drug is approved as a tumor-agnostic option only from age two, making this the first documented first-line use under one year.
Catalog record
| CREATOR | Anna-Sophia Mast, Ursula Leuschner, Stefanie Schulte, Markus Mezger, Martin Ebinger |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |